Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy in a Real-World Setting

NCT07358078 is registered in ClinicalTrials.gov with Alnylam Pharmaceuticals as lead sponsor.

NCT NCT07358078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07358078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy in a Real-World Setting
Lead sponsor
Alnylam Pharmaceuticals
Phase
Observational
Overall status
Recruiting
Start date
January 9, 2026
Completion date
October 23, 2030
Enrollment
2,000 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

transthyretin amyloidosis with cardiomyopathy